# Safety and therapeutic potential evaluation of Cefotaxime plus Polymyxin B against polymyxin-carbapenem resistant Klebsiella pneumoniae in a murine model

## TL;DR

This study tests the safety and effectiveness of combining Cefotaxime and Polymyxin B against drug-resistant Klebsiella pneumoniae in mice.

## Contribution

The study demonstrates the therapeutic potential of a Cefotaxime/Polymyxin B combination against polymyxin-carbapenem-resistant Klebsiella pneumoniae in a murine model.

## Key findings

- CTX/PMB significantly reduced blood bacterial load in infected mice.
- Higher CTX doses may increase PMB-associated toxicity, as seen in kidney and liver changes.
- The combination improved clinical condition compared to monotherapies or no treatment.

## Abstract

This study aimed to evaluate the toxicity and antibacterial efficacy of Cefotaxime/Polymyxin B combination (CTX/PMB) against a polymyxin-carbapenem-resistant (PC-R) Klebsiella pneumoniae strain, using a mice model.

A single-dose toxicity assay was conducted in BALB/c mice, divided into control and CTX/PMB-treated groups receiving low, medium, or high CTX doses. Body weight, food, and water intake were monitored for 14 days. After euthanasia, organ weights and plasma biochemical markers were analyzed. Medium- and high-dose groups maintained stable weight and intake. High-dose mice exhibited reduced right kidney and liver weights and elevated urea levels. Creatinine was at the upper limit in all groups, including one control mouse. For antimicrobial efficacy, BALB/c neutropenic mice infected with PC-R K. pneumoniae K18 were assigned to naïve, mock-treated, CTX, PMB, or CTX/PMB groups. Treatments were given every 12 h, and after 24 h, blood was collected to quantify bacterial load. CTX/PMB significantly reduced blood bacterial load and improved clinical condition compared to other groups.

CTX/PMB showed therapeutic potential in treating PC-R K. pneumoniae. However higher CTX doses may potentiate PMB-associated toxicity. These findings encourage further investigation in advanced preclinical models and clinical settings to fully elucidate CTX/PMB therapeutic potential and optimize dosing regimens.